Warnex Inc.'s Influenza A H1N1 Virus Test will be Distributed by Biron

LAVAL, QUEBEC--(Marketwire - September 09, 2009) - Warnex Inc. (TSX: WNX) announced today that its Medical Laboratories division has signed a distribution agreement with Biron-Laboratoire medical, a Quebec-based provider of diagnostic and medical treatment services. According to the terms of the agreement, Biron will promote and distribute Warnex’s test for the influenza A H1N1 virus, specifically targeting industrial companies.

“With the possibility of a significant incidence rate of the pandemic A H1N1 flu virus this fall, companies are increasingly concerned with the effect this might have on their workforce,” said Mark Busgang, President and CEO of Warnex. “With Warnex’s test for the A H1N1 flu virus, which offers results in as little as 8 hours, employees may receive diagnosis earlier, allowing company decision makers to rapidly take appropriate action to limit the spread of infection to the rest of their workforce.”

“Biron has a strong corporate and industrial presence and we are proud to offer the A H1N1 diagnostic test to these clients. Along with the seasonal influenza vaccination, still recommended by the World Health Organization, the A H1N1 diagnostic test will offer our clients the best tool currently available to better control a pandemic situation in the workplace,” said Eve-Lyne Biron, President of Biron-Laboratoire medical. Unfortunately, the availability of the A H1N1 vaccine is not yet determined.”

Influenza A H1N1 virus, also known as human swine flu, is a variant of the influenza A virus which was first detected in people in April 2009 and has been declared a pandemic by the World Health Organization. The A H1N1 flu virus spreads from person to person, probably in much the same way as regular seasonal influenza viruses. The symptoms of this new flu virus are similar to the symptoms of seasonal flu and include fever, cough, sore throat, runny or stuffy nose, body aches, headache, chills and fatigue. A significant number of people who have been infected with this virus have also reported diarrhea and vomiting. Also, like seasonal flu, this virus can cause severe illness and death.

Warnex uses RT-PCR technology to specifically detect the influenza A virus including the A H1N1 strain. Warnex offers an accelerated service whereby results are provided in as little as 8 hours. Warnex also recently launched a test that specifically detects the H275Y mutation of the pandemic influenza A H1N1 virus, which is associated with resistance to Tamiflu®, a drug used for the treatment and prevention of the flu.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

About Biron

Biron delivers innovative medical tests, which meet high quality and reliability standards, to health care and life sciences professionals, the general population and private organizations. We provide the latest biological assay and biochemical-marker services that are easily accessible through an integrated network of collection sites and through flexible processing of analysis reports, all within a meticulous quality control environment. Biron-Laboratoire medical was founded in 1952 and currently operates more than 100 sites throughout Quebec. Biron-Laboratoire medical is part of Biron Groupe sante Inc., which also owns Biron-Soins du sommeil, a leading provider of diagnosis and treatment of sleep disorders.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex’s most recent Management’s Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.